Trial · NCT01340885
Cognitive Decline in Non-demented PD
NCT01340885, Phase 4, Completed, Oregon Health and Science University; results first posted 2020-07-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cognitive Decline in Non-demented PD. Trials, record NCT01340885. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01340885
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cognitive Decline in Non-demented PD
- NCT number
- NCT01340885
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 9 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Parkinson's Disease
- Interventions
- Strattera, Exelon, Placebo
- First posted
- 2011-04-25
- Last updated
- 2020-07-07
- Results first posted
- 2020-07-07
- Limitations and caveats
Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful.
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Attention Network Effects | 6 weeks | |
| Secondary | Quality of Life | 6 weeks | PDQ-39 |
| Secondary | Stroop Color Word Test | 6 weeks | |
| Secondary | Fatigue | 6 weeks | |
| Secondary | Depression | 6 weeks | |
| Secondary | Daytime Sleepiness | 6 weeks |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Attention Network Effects | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. | ||
| SECONDARY | Quality of Life | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. | ||
| SECONDARY | Stroop Color Word Test | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. | ||
| SECONDARY | Fatigue | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. | ||
| SECONDARY | Depression | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. | ||
| SECONDARY | Daytime Sleepiness | 6 weeks | Study did not enroll enough subjects to reach meaningful results at the time of original conduct. While study data are/were retained per investigator responsibility, sincere attempts to access these data for retrospective analysis were unsuccessful. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atomoxetine | 0 | |
| Overall Study | STARTED | Rivastigimine | 0 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Atomoxetine | 0 | |
| Overall Study | COMPLETED | Rivastigimine | 0 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Atomoxetine | 0 | |
| Overall Study | NOT COMPLETED | Rivastigimine | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atomoxetine | 0 | 0 |
| Total, all-cause mortality | Rivastigimine | 0 | 0 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Atomoxetine | 0 | 0 |
| Total, other adverse events | Rivastigimine | 0 | 0 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Atomoxetine | 0 | 0 |
| Total, serious adverse events | Rivastigimine | 0 | 0 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P50NS062684 | Pacific Udall Center | MONTINE, THOMAS J | STANFORD UNIVERSITY | NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE | 2009 to 2020 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01340885
GET https://conductscience.org/api/trials/v1/NCT01340885/registered